Company: BIAF
Filing Date: 2025-09-15
Form Type: S-1/A
Source: 0001493152-25-013294
Chunk: 3

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-09-15
Form: S-1/A
Chunk 3
---
 of a financial advisory
agreement dated as of August 13, 2025, (the “Advisory Agreement”) and (b) 129,130 shares of Common Stock issuable upon the
exercise of warrants (the “Placement Agent Warrants”) to purchase 129,130 shares of Common Stock (the “Placement Agent
Warrant Shares”) were partial compensation for WallachBeth acting as placement agent in connection with the August 2025 Private
Placement pursuant to the terms of a placement agency agreement dated as of August 13, 2025, (the “Placement Agency Agreement”).
Each of the August 2025 Private Placement and the Warrant Inducement Private Placement closed on August 14, 2025. The Investors, the
Warrant Inducement Holders, the May 2025 Warrant Holders and the designees of WallachBeth that received Inducement Advisor Warrants
and/or Placement Agent Warrants are collectively referred to herein as the “Selling Stockholders.” The Private Warrants,
the Inducement Warrants, the Inducement Advisor Warrants, the May 2025 Warrants and the Placement Agent Warrants are collectively
referred to herein as the “Common Warrants.” The Conversion Shares, Private Warrant Shares, the Inducement Warrant Shares,
the Inducement Advisor Warrant Shares the May 2025 Warrant Shares and the Placement Agent Warrant Shares are collectively referred
to herein as the “Resale Shares.”

We are filing this registration statement on Form S-1, of which this prospectus forms a part, to fulfill our contractual obligations to provide for the registration of the resale of the Common Warrant Shares by Selling Stockholders. See “Selling Stockholders” beginning on page 12 of this prospectus for more information about the Selling Stockholders. The registration of the shares of Common Stock to which this prospectus relates does not require the Selling Stockholders to sell any of their shares of our Common Stock.

We are not offering any shares of Common Stock under this prospectus and will not receive any proceeds from the sale or other disposition of the shares of our Common Stock covered hereby. However, we will receive the proceeds from any exercise of the Common Warrants for cash. See “Use of Proceeds” beginning on page 11 of this prospectus.

The Selling Stockholders identified in this prospectus, or their pledgees, assignees, donees, transferees or their respective successors-in-interest